201 related articles for article (PubMed ID: 33002328)
1. Loss of CD38 expression in myelomatous pleural effusion in a patient with myeloma treated with daratumumab: Report of a case.
Sasaki N; Ishida K; Yanagawa N; Nishiya M; Yashima-Abo A; Kikuchi I; Yamada N; Ambo J; Kiyohara K; Osakabe M; Uesugi N; Ito S; Sugai T
Diagn Cytopathol; 2021 Jan; 49(1):168-170. PubMed ID: 33002328
[No Abstract] [Full Text] [Related]
2. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.
Pick M; Vainstein V; Goldschmidt N; Lavie D; Libster D; Gural A; Grisariu S; Avni B; Ben Yehuda D; Gatt ME
Eur J Haematol; 2018 May; 100(5):494-501. PubMed ID: 29453884
[TBL] [Abstract][Full Text] [Related]
3. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.
Choudhry P; Mariano MC; Geng H; Martin TG; Wolf JL; Wong SW; Shah N; Wiita AP
Leukemia; 2020 Mar; 34(3):938-941. PubMed ID: 31595037
[No Abstract] [Full Text] [Related]
4. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.
Oberle A; Brandt A; Alawi M; Langebrake C; Janjetovic S; Wolschke C; Schütze K; Bannas P; Kröger N; Koch-Nolte F; Bokemeyer C; Binder M
Haematologica; 2017 Sep; 102(9):e368-e370. PubMed ID: 28522580
[No Abstract] [Full Text] [Related]
5. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
6. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Nijhof IS; Casneuf T; van Velzen J; van Kessel B; Axel AE; Syed K; Groen RW; van Duin M; Sonneveld P; Minnema MC; Zweegman S; Chiu C; Bloem AC; Mutis T; Lokhorst HM; Sasser AK; van de Donk NW
Blood; 2016 Aug; 128(7):959-70. PubMed ID: 27307294
[TBL] [Abstract][Full Text] [Related]
7. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.
Minarik J; Novak M; Flodr P; Balcarkova J; Mlynarcikova M; Krhovska P; Pika T; Pikalova Z; Bacovsky J; Scudla V
Eur J Haematol; 2017 Aug; 99(2):186-189. PubMed ID: 28470777
[TBL] [Abstract][Full Text] [Related]
8. Myelomatous effusion with poor response to chemotherapy.
Kim YM; Lee KK; Oh HS; Park SK; Won JH; Hong DS; Park HS; Park JS; Lee DW
J Korean Med Sci; 2000 Apr; 15(2):243-6. PubMed ID: 10803706
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
Cho N; Ko S; Shokeen M
Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
Sanchez L; Wang Y; Siegel DS; Wang ML
J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
[TBL] [Abstract][Full Text] [Related]
11. VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.
Courville EL; Yohe S; Shivers P; Linden MA
Am J Clin Pathol; 2020 Jan; 153(2):221-228. PubMed ID: 31679012
[TBL] [Abstract][Full Text] [Related]
12. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
13. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
Zannetti BA; Faini AC; Massari E; Geuna M; Maffini E; Poletti G; Cerchione C; Martinelli G; Malavasi F; Lanza F
Cells; 2020 Dec; 9(12):. PubMed ID: 33322499
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
Saltarella I; Desantis V; Melaccio A; Solimando AG; Lamanuzzi A; Ria R; Storlazzi CT; Mariggiò MA; Vacca A; Frassanito MA
Cells; 2020 Jan; 9(1):. PubMed ID: 31936617
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK
Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602
[TBL] [Abstract][Full Text] [Related]
18.
Quelven I; Monteil J; Sage M; Saidi A; Mounier J; Bayout A; Garrier J; Cogne M; Durand-Panteix S
J Nucl Med; 2020 Jul; 61(7):1058-1065. PubMed ID: 31862796
[TBL] [Abstract][Full Text] [Related]
19. Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody.
Seth A; Murray D; Buadi FK; Gertz MA; Yadav U; Kumar SK; Gonsalves WI
Eur J Haematol; 2023 Aug; 111(2):318-321. PubMed ID: 37209032
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.
Sullivan HC; Gerner-Smidt C; Nooka AK; Arthur CM; Thompson L; Mener A; Patel SR; Yee M; Fasano RM; Josephson CD; Kaufman RM; Roback JD; Lonial S; Stowell SR
Blood; 2017 Jun; 129(22):3033-3037. PubMed ID: 28373263
[No Abstract] [Full Text] [Related]
[Next] [New Search]
